Disease · MONDO_0005277
Comparisons in its trials218
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 218
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Lasmiditan 100mg vs Lasmiditan 200mg: Number of Participants With at Least 1 Treatment Emergent Adverse Event | 447 of 991 | 545 of 1,039 | 2,030 | NCT02565186 | Trial comparisons |
| Lasmiditan 100mg vs Lasmiditan 200mg: deaths from any cause | 0 of 991 | 0 of 1,039 | 2,030 | NCT02565186 | Trial comparisons |
| Lasmiditan 100mg vs Lasmiditan 200mg: serious adverse events | 29 of 991 | 36 of 1,039 | 2,030 | NCT02565186 | Trial comparisons |
| STS101 5.2 mg vs STS101 Placebo: deaths from any cause | 0 of 731 | 0 of 729 | 1,460 | NCT04940390 | Trial comparisons |
| STS101 5.2 mg vs STS101 Placebo: serious adverse events | 3 of 731 | 0 of 729 | 1,460 | NCT04940390 | Trial comparisons |
| STS101 5.2 mg vs STS101 Placebo: Percentage of Subjects With Freedom From Most-Bothersome Symptom at 2 Hours Post Dose | 265 of 716 | 230 of 708 | 1,424 | NCT04940390 | Trial comparisons |
| STS101 5.2 mg vs STS101 Placebo: Percentage of Subjects With Freedom From Migraine Headache Pain at 2 Hours Post Dose | 146 of 716 | 124 of 708 | 1,424 | NCT04940390 | Trial comparisons |
| STS101 5.2 mg vs STS101 Placebo: Percentage of Subjects With Relief From Migraine Headache Pain at 2 Hours Post Dose | 379 of 716 | 316 of 708 | 1,424 | NCT04940390 | Trial comparisons |
| Rimegepant vs Triptans: Number of Participants With Family Practitioner Visits in Past 6 Months- Primary Analysis | 102 of 135 | 979 of 1,260 | 1,395 | NCT06680206 | Trial comparisons |
| Rimegepant vs Triptans: Number of Participants With Emergency Room (ER) Visits in Past 6 Months- Primary Analysis | 36 of 135 | 334 of 1,260 | 1,395 | NCT06680206 | Trial comparisons |
| Rimegepant vs Triptans: Number of Participants With Traditional Healthcare Provider Visits in Past 6 Months- Primary Analysis | 132 of 135 | 1,228 of 1,260 | 1,395 | NCT06680206 | Trial comparisons |
| Rimegepant vs Triptans: Number of Participants With Cardiologist Visits in Past 6 Month- Primary Analysis | 21 of 135 | 130 of 1,260 | 1,395 | NCT06680206 | Trial comparisons |
| Rimegepant vs Triptans: Number of Participants With Hospitalizations in Past 6 Months- Primary Analysis | 15 of 135 | 147 of 1,260 | 1,395 | NCT06680206 | Trial comparisons |
| Rimegepant vs Triptans: Number of Participants With Neurologist Visits in Past 6 Months - Primary Analysis | 72 of 135 | 374 of 1,260 | 1,395 | NCT06680206 | Trial comparisons |
| Rimegepant 75 mg ODT vs Placebo: deaths from any cause | 0 of 682 | 0 of 693 | 1,375 | NCT03461757 | Trial comparisons |
| Rimegepant 75 mg ODT vs Placebo: serious adverse events | 0 of 682 | 0 of 693 | 1,375 | NCT03461757 | Trial comparisons |
| Rimegepant (Users With <12 Days of Use) vs Triptans: Number of Participants With Hospitalizations in Past 6 Months- Sensitivity Analysis | 11 of 103 | 111 of 1,257 | 1,360 | NCT06680206 | Trial comparisons |
| Rimegepant (Users With <12 Days of Use) vs Triptans: Number of Participants With Neurologist Visits in Past 6 Months- Sensitivity Analysis | 57 of 103 | 358 of 1,257 | 1,360 | NCT06680206 | Trial comparisons |
| Rimegepant (Users With <12 Days of Use) vs Triptans: Number of Participants With Emergency Room (ER) Visits in Past 6 Months- Sensitivity Analysis | 27 of 103 | 301 of 1,257 | 1,360 | NCT06680206 | Trial comparisons |
| Rimegepant (Users With <12 Days of Use) vs Triptans: Number of Participants With Cardiologist Visits in Past 6 Months- Sensitivity Analysis | 14 of 103 | 137 of 1,257 | 1,360 | NCT06680206 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005277/comparisons